Why the study?
DOX-DNA cross-links are unstable to heat and alkali during standard biochemical isolation, obscuring the clinical relevance of this mechanism.
A novel single-molecule magnetic tweezers assay reveals that doxorubicin has a much higher DNA cross-link formation ability at clinically relevant concentrations than previously estimated by bulk measurements.
May refine doxorubicin genotoxicity models at low doses; leaves open validation in cellular systems before broader implications.
Doxorubicin (DOX) ranks among the most effective anticancer agents. Increasing the formation of covalent DOX-DNA interstrand cross-links can improve the anticancer activity of DOX. However, due to the low stability of the DOX-DNA cross-links to heat and alkali, DOX can be extensively lost during isolation procedures of biochemical methods, thus reducing the apparent clinical relevance of this mechanism. Here, we developed a drug label-free, single-molecule magnetic tweezers assay that can detect a single DOX-DNA cross-link on the basis of the significant increase of the unzipping forces of DNA hairpins upon drug binding. Using this assay, we measured the DOX concentration-dependent cross-linking rates at clinically relevant concentrations of DOX. We report an ∼26-fold higher formaldehyde concentration dependence of cross-linking rates than previously reported and 0.9 ± 0.8 cross-links/103 bp at the clinically relevant concentrations of 70 nM DOX and 50 μM formaldehyde. Our results suggest a much higher cross-link formation ability than previous bulk measurements have reported and suggest that the cross-linking mechanism has promising therapeutic potential. This general method can be used to detect the formation kinetics of other DNA lesions or DNA adducts that affect DNA duplex stability.
No takes yet. Share an insight, caveat, or question.
Pei et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: